Presentation is loading. Please wait.

Presentation is loading. Please wait.

ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho First Example in Respiratory Area  Steroid Nasal Spray  Seasonal Allergic Rhinitis, Age  12 yr 

Published byJosephine Kennedy Modified over 8 years ago

Similar presentations

Presentation on theme: "ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho First Example in Respiratory Area  Steroid Nasal Spray  Seasonal Allergic Rhinitis, Age  12 yr "— Presentation transcript:

1 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho First Example in Respiratory Area  Steroid Nasal Spray  Seasonal Allergic Rhinitis, Age  12 yr  Randomized, Double-Blind, Parallel-Group  5-21 Days of Screening Followed by 2 Weeks of Treatment  Placebo, 50mcg, 100mcg, 200mcg, 400mcg,  ~ 125 Patients/Treatment.

2 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Primary Efficacy & Key Safety Endpoints  Mean change from baseline over the entire treatment period in daily, reflective total nasal symptom scores (rTNSS)  Adverse events  24-hour urinary cortisol excretion

3 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Primary Efficacy Endpoint Mean Change in Daily rTNSS over Treatment Period Day

4 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Primary Efficacy Endpoint Mean Change in Daily rTNSS over Entire Treatment Period

5 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Onset of Action Mean Change in AM Pre-dose iTNSS Hour

6 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho “Important” Efficacy Endpoint Mean changes in AM pre-dose iTOSS over Entire Treatment Period

7 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Adverse Events during Treatment Period

8 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho 24-hour Urinary Cortisol Excretion Change from Baseline to Week 2 (UC pop)

9 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Dose Selection  Which dose would you choose?  Why?

10 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Discussion  Flat Dose Response Pattern for steroids, once a particular does starts to work, all higher doses work?  Why not study more lower doses, e.g. 25 mcg, or even 12.5 mcg?  Why not use active control (market leader) to better asses relative efficacy and safety?  Why not wait until the final formulation and final device are developed?

11 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Second Example in Respiratory Area  A Novel Compound  COPD (Chronic Obstructive Pulmonary Disease) – Smoker’s Lung  Randomized, Double-Blind, Parallel-Group, >40 yrs  2 Weeks Run-in Followed by 4 Weeks of Treatment  Placebo, 5mg, 10mg, 15mg.  ~105 Patients/Treatment

12 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho One of the Primary Efficacy Endpoints Change from baseline in trough FEV 1 at Endpoint –Measured in AM prior to dosing

13 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Phase II Study Results Dose5mg10mg15mg FEV 1 (Trt – Plb) 60ml10ml140ml (Endpoint at 4 wks)

14 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Phase III Study Results Study 1234 FEV 1 (15mg-Plb) 40ml20ml30ml30ml (Average Over Time) FEV 1 (15mg-Plb) 80ml40ml30ml40ml (Endpoint at 24 wks)

15 ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho Discussion  A successful phase II does ranging study does not guarantee phase III successes – Duh!  Is it Preventable?  If you say yes, then how?

Download ppt "ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho First Example in Respiratory Area  Steroid Nasal Spray  Seasonal Allergic Rhinitis, Age  12 yr "

Similar presentations

Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.

Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
UPLIFT Understanding Potential Long-term Impacts on Function with Tiotropium Adapted from Tashkin et al. NEJM 2008: 359:1543-54. Please be advised that.

UPLIFT Understanding Potential Long-term Impacts on Function with Tiotropium Adapted from Tashkin et al. NEJM 2008: 359: Please be advised that.
Figure 1. Higher prevalence of significant GER symptoms in patients with COPD. The prevalence of significant GER symptoms (heartburn and/or regurgitation.

Figure 1. Higher prevalence of significant GER symptoms in patients with COPD. The prevalence of significant GER symptoms (heartburn and/or regurgitation.
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.
Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.

Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.

Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
NDAC December 14, 2007 1 Clinical Endpoints for Nasal Decongestants Xu Wang, M.D., Ph.D. Medical Officer Division of Pulmonary and Allergy Products Nonprescription.

NDAC December 14, Clinical Endpoints for Nasal Decongestants Xu Wang, M.D., Ph.D. Medical Officer Division of Pulmonary and Allergy Products Nonprescription.
Badrul A. Chowdhury, MD, PhD

Badrul A. Chowdhury, MD, PhD
HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;

HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;
High-Throughput Screening Speeding Up CF Drug Discovery >10,000 Primary assays/day High-throughput screening CFTR Modulator Drug SAR based Medicinal Chemistry.

High-Throughput Screening Speeding Up CF Drug Discovery >10,000 Primary assays/day High-throughput screening CFTR Modulator Drug SAR based Medicinal Chemistry.
Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.

Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.

Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.

ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.
Rapivab™ - peramivir injection

Rapivab™ - peramivir injection
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.

Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Similar presentations

Ads by Google